Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Using intraoperative radiation to eliminate pancreatic cancer cells that have spread to areas around the pancreas, investigators at Johns Hopkins have been able to reduce the recurrence rate around the pancreas to 5%.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Researchers develop technique to track chemotherapy drug inside cells

Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Shortened version of HER2 protein may drive treatment resistance in breast cancer, Mayo study finds

Mayo Clinic researchers have discovered why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Enhancing the body’s “first responder” cells may boost immune therapy, Mayo study finds

Mayo Clinic researchers have identified a specific immune cell that can be targeted to give a boost to standard immunotherapies for cancer. Two research teams, working collaboratively but using distinct approaches, found that “first-responder” immune cells known as myeloid cells can be manipulated to enhance the activity of tumor-killing T cells.

October 31, 2025

Vol.51 No.40

Drugs & Targets

EC approves Keytruda combination for a head-and-neck indication

The European Commission approved Keytruda (pembrolizumab), an anti-PD-1 therapy, as a monotherapy for the treatment of resectable locally advanced head-and-neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score ≥1.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

Mayo Clinic administered an investigational radioactive medicine to a patient with hepatocellular carcinoma.

October 17, 2025

Vol.51 No.38

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

YOU MAY BE INTERESTED IN

Targeted radiation during surgery reduces pancreatic cancer recurrence, Hopkins study finds

Researchers develop technique to track chemotherapy drug inside cells

Shortened version of HER2 protein may drive treatment resistance in breast cancer, Mayo study finds

Enhancing the body’s “first responder” cells may boost immune therapy, Mayo study finds

EC approves Keytruda combination for a head-and-neck indication

Mayo tests radiopharmaceutical theranostic for HCC in first-in-human trial

Renew today!

Subscriber content

Never miss an issue!

Login